Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: Journal Article
Number of items: 3.

Journal Article

Gluz, Oleg, Nitz, Ulrike, Kolberg-Liedtke, Cornelia, Prat, Aleix ORCID: 0000-0003-2377-540X, Christgen, Matthias, Kuemmel, Sherko, Mohammadian, Mohammad Parsa, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Wuerstlein, Rachel, Graeser, Monika, Pelz, Enrico, Jozwiak, Katarzyna ORCID: 0000-0002-9614-6586, Zu Eulenburg, Christine, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clin. Cancer Res., 28 (22). S. 4995 - 5004. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Grote, Isabel ORCID: 0000-0002-6731-187X, Bartels, Stephan, Kandt, Leonie, Bollmann, Laura, Christgen, Henriette, Gronewold, Malte, Raap, Mieke, Lehmann, Ulrich, Gluz, Oleg, Nitz, Ulrike, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Zu Eulenburg, Christine, Braun, Michael, Aktas, Bahriye, Grischke, Eva-Maria, Schumacher, Claudia, Luedtke-Heckenkamp, Kerstin, Kates, Ronald, Wuerstlein, Rachel, Graeser, Monika, Harbeck, Nadia, Christgen, Matthias and Kreipe, Hans (2021). TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med., 10 (23). S. 8581 - 8595. HOBOKEN: WILEY. ISSN 2045-7634

Nitz, Ulrike, Gluz, Oleg, Graeser, Monika, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Augustin, Doris, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, Zu Eulenburg, Christine, Kates, Ronald, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol., 23 (5). S. 625 - 636. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

This list was generated on Tue Apr 23 10:52:54 2024 CEST.